SAN.PA : Summary for SANOFI - Yahoo Finance

U.S. Markets closed

Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
82.36-0.96 (-1.15%)
At close: 5:37PM CEST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close83.32
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range82.29 - 83.09
52 Week Range62.50 - 86.05
Avg. Volume2,200,992
Market Cap103.78B
PE Ratio (TTM)22.68
Earnings DateN/A
Dividend & Yield3.35 (3.72%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales
    Investor's Business Daily2 days ago

    Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales

    Amgen trumped Regeneron and Sanofi this week as prescriptions of its cholesterol-cutting drug grew.

  • Reuters2 days ago

    EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

    A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis. The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Kevzara, citing its ability to reduce the signs and symptoms of rheumatoid arthritis. Sarilumab, the active substance of Kevzara, a treatment for adult patients with moderate to severe rheumatoid arthritis, works by blocking a protein called IL-6, which is associated with inflammation.

  • Reuters3 days ago

    Regulator links Sanofi epilepsy drug to child deformities

    Up to 4,100 children in France suffered major malformations in the womb after their mothers took a treatment against epilepsy and bipolar disorders known as valproate between 1967 and 2016, France's drug regulator said. Valproate, which has been manufactured in France by Sanofi under the brand Depakine for epilepsy and Depakote and Depamide for bipolar disorders, is also believed to cause slow neurological development, ANSM said on Thursday.